Cite
HARVARD Citation
Collins, G. et al. (n.d.). Safety and efficacy of single‐agent ibrutinib in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL): A multicenter, open‐label, phase 2 study. Hematological oncology. pp. 211-212. [Online].